Skip to main content
SpringerLink
Log in

Hormonal therapies of metastatic breast cancer: the past and the present

  • Chapter
Metastasis of Breast Cancer

Part of the book series: Cancer Metastasis – Biology and Treatment ((CMBT,volume 11))

  • 1192 Accesses

Abstract

Endocrine therapy of metastatic breast cancer has been established for more than a century. Following the discovery of the beneficial effects of oophorectomy by Beatson in 1896 and the identification of the first estrogen receptor (ER- ) by E. Jensen 70 years later (1967), antihormonal treatment of breast cancer represented not only the first systemic treatment strategy in oncology but also the first for which a clear scientific rationale has been established. While early treatment options (either surgical or additive drug treatment) were associated with significant side effects, the partial estrogen receptor antagonist tamoxifen established modern endocrine drug therapy of metastatic breast cancer. The compound became the most widely used drug in breast cancer therapy until now. Recently, the role of tamoxifen has been challenged following development of other novel, highly potent, and selective drugs. The most important improvement has certainly been made with the implementation of the third generation of aromatase inhibitors (anastrozole, letrozole, and exemestane). These compounds are now in general used as first-line therapy in metastatic breast cancer in postmenopausal women not exposed to the compounds in the adjuvant setting for those relapsing after adjuvant therapy with an aromatase inhibitor. In addition, SERDs (selective estrogen receptor downregulators) like fulvestrant have shown clinical efficacy and have been introduced in standard care as well. The present publication provides an overview about endocrine treatment options of metastatic breast cancer and discusses possible treatment algorithms for both pre-and postmenopausal breast cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Koenders PG, Beex LVAM, Kloppenborg PWC, Smals AGH, Benraad TJ, Group BCS. Human breast cancer: survival from first metastasis. Breast Cancer Res Treat 1992; 21:173-180.

    Article  PubMed  CAS  Google Scholar 

  2. Bruzzi P, Del Mastro L, Sormani MP, Bastholt L, Danova M, Focan C, et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. Journal of Clinical Oncology 2005; 23(22):5117-5125.

    Article  PubMed  Google Scholar 

  3. May E, Mouriesse H, May-Levin F, Qian JF, May P, Delarue JC. Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erB-2 overexpression. Br J Cancer 1990; 62:430-435.

    PubMed  CAS  Google Scholar 

  4. Paterson AHG, Zuck VP, Szafran O, Lees AW, Hanson J. Influence and significance of certain prognostic factors on survival in breast cancer. Eur J Cancer Clin. Oncol. 1982; 18(10):937-943.

    Article  PubMed  CAS  Google Scholar 

  5. Howell A, Harland RNL, Bramwell VHC, Swindell R, Barnes DM, Redford J, et al. Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet 1984; 1:588-591.

    Article  PubMed  CAS  Google Scholar 

  6. Kamby C, Rasmussen BR, Kristensen B. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer 1989; 60:252-257.

    PubMed  CAS  Google Scholar 

  7. Stewart JF, King RJB, Sexton SA, Millis RR, Rubens RD, Hayward JL. Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 1981; 17(4):449-453.

    PubMed  CAS  Google Scholar 

  8. Lønning PE, Taylor PD, Anker G, Iddon J, Wie L, Jorgensen LM, et al. High- dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001;67(2):111-116.

    Article  PubMed  Google Scholar 

  9. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2:104-107.

    Article  Google Scholar 

  10. NissenMeyer R. Ovarian irradiation and its supplement by additive hormonal treatment. Hormones and Breast Cancer 1976; 58:131-158.

    Google Scholar 

  11. Lønning PE, Lien EA, Lundgren S, Kvinnsland S. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin. Pharmacokinet. 1992; 22: 327-358.

    Article  PubMed  Google Scholar 

  12. Eidne KA, Flanagan CA, Millar RP. Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 1985; 229:989-992.

    Article  PubMed  CAS  Google Scholar 

  13. Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN, et al. A multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An intergroup study. J Clin Oncol 1998; 16(3):994-999.

    PubMed  CAS  Google Scholar 

  14. Dao TL, Huggins C. Bilateral adrenalectomy in the treatment of cancer of the breast. Arch Surg 1955; 71:645-657.

    Google Scholar 

  15. Luft R, Olivecrona H, Sjögren B. Hypophysektomy in man. Nord Med 1952; 14:351-354.

    Google Scholar 

  16. Couzinet B, Meduri G, Lecce M, Young J, Brailly S, Loosfelt H, et al. The post- menopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab 2001; 86:5060-5066.

    Article  PubMed  CAS  Google Scholar 

  17. Sluijmer AV, Heineman MA, Jong FHd, Evers JLH. Endocrine activity of the postmenopausal ovary: The effects of pituitary down-regulation and oophorectomy. J Clin Endocrinol Metab 1995; 80:2163-2167.

    Article  PubMed  CAS  Google Scholar 

  18. Dowsett M, Cantwell B, Lal A, Jeffcoate SL, Harris AL. Suppression of postmeno- pausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin. J Clin Endocrinol Metab 1988; 66:672-677.

    Article  PubMed  CAS  Google Scholar 

  19. Lønning PE. New endocrine drugs for treatment of advanced breast cancer. Acta Oncol 1990; 29:379-386.

    Article  PubMed  Google Scholar 

  20. Cash R, Brough AJ, Cohen MNP, Satoh PS. Aminoglutethimide (Elipten-Ciba) is an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. J Clin Endocrinol Metab 1967; 27:1239-1248.

    Article  PubMed  CAS  Google Scholar 

  21. Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E, Ruby E. Aminoglutethi- mide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 1978; 47:1257-1265.

    Article  PubMed  CAS  Google Scholar 

  22. Samojlik E, Veldhuis JD, Wells SA, Santen RJ. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma. J Clin Invest 1980; 65:602-612.

    Article  PubMed  CAS  Google Scholar 

  23. Lønning PE, Kvinnsland S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 1988; 35:685-710.

    Article  PubMed  Google Scholar 

  24. Brodie AMH, Schwarzel WC, Shaikh AA, Brodie HJ. The effect of an aromatase inhbitor, 4-hydroxy-androstene-3,17-dione, on estrogen-dependent pro- cesses in reproduction and breast cancer. Endocrinology 1977; 100:1684-1695.

    Article  PubMed  CAS  Google Scholar 

  25. Miller WR, Dixon JM. Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin Breast Cancer 2000;1 (Suppl. 1):9-14.

    Article  Google Scholar 

  26. Santen RJ, Lipton A, Kendall J. Successful medical adrenalectomy with amino- glutethimide. JAMA 1974; 230(12):1661-1665.

    Article  PubMed  CAS  Google Scholar 

  27. Young JA, Newcomer LN, Keller AM. Aminoglutethimide-induced bone marrow injury. Cancer 1984; 54:1731-1734.

    Article  PubMed  CAS  Google Scholar 

  28. Dowsett M, Cunningham DC, Stein RC, Evans S, Dehennin L, Hedley A, et al. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 1989; 49:1306-1312.

    PubMed  CAS  Google Scholar 

  29. Dowsett M, Mehta A, King N, Smith IE, Powles TJ, Stein RC, et al. An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients. Eur J Cancer 1992; 28:415-420.

    Article  PubMed  CAS  Google Scholar 

  30. Dowsett M, Lloyd P. Comparison of the pharmacokinetics and pharmaco- dynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men. Cancer Chemother. Pharmacol. 1990; 27:67-71.

    CAS  Google Scholar 

  31. Lønning PE, Skulstad P, Sunde A, Thorsen T. Separation of urinary metabolites of radiolabelled estrogens in man by HPLC. J. Steroid Biochem. 1989; 32:91-97.

    Article  PubMed  Google Scholar 

  32. Jacobs S, Lønning PE, Haynes B, Griggs L, Dowsett M. Measurement of aromati- sation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. J Enzyme Inhibition 1991; 4:315-325.

    Article  CAS  Google Scholar 

  33. Lønning PE, Jacobs S, Jones A, Haynes B, Powles T, Dowsett M. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br J Cancer 1991; 63:789-793.

    PubMed  Google Scholar 

  34. Geisler J, Lønning PE. Aromatase inhibition - translation into a successful therapeutic approach. Clin Cancer Res 2005; 11:2809-2821.

    Article  PubMed  CAS  Google Scholar 

  35. Thürlimann B, Beretta K, Bacchi M, Castiglionegertsch M, Goldhirsch A, Jungi WF, et al. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer - Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 1996; 7(5):471-479.

    PubMed  Google Scholar 

  36. Falkson CI, Falkson HC. A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer. Ann Oncol 1996; 7(5):465-469.

    PubMed  CAS  Google Scholar 

  37. Thürlimann B, Castiglione M, HsuSchmitz SF, Cavalli F, Bonnefoi H, Fey MF, et al. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Eur J Cancer 1997; 33(7):1017-1024.

    Article  PubMed  Google Scholar 

  38. Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, et al. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma. Results of two randomized double blind controlled multiinstitutional trials. Cancer 1996; 77(12):2503-2513.

    Article  PubMed  CAS  Google Scholar 

  39. Pérez-Carrión R, Candel VA, Calabresi F, Michel RT, Santos R, Delozier T, et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 1994; 5:S19-S24.

    PubMed  Google Scholar 

  40. Bonneterre J, Buzdar A, Nabholtz J-M, Robertson J, Thürlimann B, von Euler M, et al. Anastrozole is superior to Tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92(9):2247-2258.

    Article  PubMed  CAS  Google Scholar 

  41. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Doubleblind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16(2):453-461.

    PubMed  CAS  Google Scholar 

  42. Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey M, et al. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 1998; 9(6):639-645.

    Article  PubMed  CAS  Google Scholar 

  43. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in post- menopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000; 18:1399-1411.

    PubMed  CAS  Google Scholar 

  44. Paridaens R, Therasse P, Dirix L, Beex L, Piccart M, Cameron D, et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - a randomized phase III trial of the EORTC Breast Group. In: Am Soc Clin Oncol 2004, 2004; p. 6 (Abstr 515).

    Google Scholar 

  45. Furr BJA, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmac. Ther. 1984; 25:127-205.

    Article  CAS  Google Scholar 

  46. Jordan VC. Tamoxifen and tumorigenicity: A predictable concern. J Natl Cancer Inst 1995; 87:623-626.

    Article  PubMed  CAS  Google Scholar 

  47. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339(22):1609-1618.

    Article  PubMed  CAS  Google Scholar 

  48. Groom GV, Griffiths K. Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and pro- gesterone in normal pre-menopausal women. J. Endocrinol 1976; 70:421-428.

    Article  PubMed  CAS  Google Scholar 

  49. Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003; 95(11):779-790.

    PubMed  CAS  Google Scholar 

  50. Buzdar A, Hayes D, El-Khoudary A, Yan S, Lonning P, Lichinitser M, et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Research and Treatment 2002; 73(2):161-175.

    Article  PubMed  CAS  Google Scholar 

  51. Helle SI, Anker G, Tally M, Hall K, Lønning PE. Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients. J Steroid Biochem Mol Biol 1996; 57:167-171.

    Article  PubMed  CAS  Google Scholar 

  52. Geisler J, Haarstad H, Gundersen S, Raabe N, Kvinnsland S, Lønning PE. Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer. J Endocrinol 1995; 146:359-363.

    Article  PubMed  CAS  Google Scholar 

  53. Lønning PE, Hall K, Aakvaag A, Lien EA. Influence of tamoxifen on the plasma levels of insulin-like growth factor I and Insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 1992; 52:4719-4723.

    PubMed  Google Scholar 

  54. Stenbygaard LE, Herrstedt J, Thomsen JF, Svendsen KR, Engelholm SA, Dombernowsky P. Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial. Breast Cancer Res Treat 1993; 25:57-63.

    Article  PubMed  CAS  Google Scholar 

  55. Hayes DF, Zyl JAv, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995; 13:2556-2566.

    PubMed  CAS  Google Scholar 

  56. Pyrhonen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the ‘nordic’ phase III study. Br J Cancer 1997; 76(2):270-277.

    PubMed  CAS  Google Scholar 

  57. Curran M, Wiseman L. Fulvestrant. Drugs 2001; 61(6):807-813.

    Article  CAS  Google Scholar 

  58. Liu H, Wing L, De Los Reyes A, Jordan V, Lurie R. Long-term fulvestrant treatment results in irreversible loss of estrogen receptor alpha expression in mcf-7 human breast cancer cells. Proc Am Ass Cancer Res 2004; 45:1293.

    Google Scholar 

  59. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20(16):3396-3403.

    Article  PubMed  CAS  Google Scholar 

  60. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, et al. Double- blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20 (16):3386-3395.

    Article  PubMed  CAS  Google Scholar 

  61. Howell A, Robertson JE, Abram P, Lichinitser MR, Elledge R, Bajetta E, et al. Comparison of Fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. Journal of Clinical Oncology 2004; 22(9):1605-1613.

    Article  PubMed  CAS  Google Scholar 

  62. Lønning PE, Lien E. Mechanisms of action of endocrine treatment in breast cancer. Crit Rev Oncol / Haematol 1995; 21:158-193.

    Article  Google Scholar 

  63. Lundgren S, Helle SI, Lønning PE. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Clin Cancer Res 1996; 2:1515-1521.

    PubMed  CAS  Google Scholar 

  64. Jones S, Vogel C, Arkhipov A, Fehrenbacher L, Eisenberg P, Cooper B, et al. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. J Clin Oncol 1999; 17(11):3418-3425.

    PubMed  CAS  Google Scholar 

  65. Alberto P, Mermillod B, Kaplan E, Goldhirsch A, Obrecht J-P, Jungi F, et al. A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: Low response in patients previously treated with medroxyprogesterone. Eur J Cancer Clin Oncol 1985; 21:423-428.

    Article  PubMed  CAS  Google Scholar 

  66. Lea OA, Kvinnsland S, Thorsen T. Improved measurement of androgen receptors in human breast cancer. Cancer Res 1989; 49:7162-7167.

    PubMed  CAS  Google Scholar 

  67. Nosaquo ND. Androgens and estrogens in the treatment of disseminated mammary carcinoma. JAMA 1960; 172:135-147.

    Google Scholar 

  68. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, et al. Randomized clinical trial of diethylstilstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981; 304:16-21.

    Article  PubMed  CAS  Google Scholar 

  69. Lippman M, Bolan G, Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 1976; 36:4595-4601.

    PubMed  CAS  Google Scholar 

  70. Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995; 80:2918-2925.

    Article  PubMed  CAS  Google Scholar 

  71. Lønning PE, Taylor PD, Anker G, Iddon J, Wie L, Jørgensen LM, et al. High- dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine treatment. Breast Cancer Res Treat 2001; 67:111-116.

    Article  PubMed  Google Scholar 

  72. Lønning PE, Bajetta E, Murray R, TubianaHulin M, Eisenberg PD, Mickiewicz E, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial. J Clin Oncol 2000; 18(11):2234-2244.

    PubMed  Google Scholar 

  73. Carlini P, Michelotti A, Giannarelli D, Conte PF, Salvadori B, Landucci E, et al. Exemestane (EXE) is an effective 3rd line hormonal therapy for post- menopausal metastatic breast cancer (MBC) patients (pts) pretreated with 3rd generation non-steroidal aromatase inhibitors (nSAI). Ann Oncol 2002; 13 (Suppl 5):Abstra 171p, s48.

    Google Scholar 

  74. Bertelli G, Garrone O, Merlano M, Occelli M, Bertolotti L, Castiglione F, et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005; 69(6):471-477.

    Article  PubMed  CAS  Google Scholar 

  75. Robertson JFR, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - A prospective combined analysis of two multicenter trials. Cancer 2003; 98(2):229-238.

    Article  PubMed  CAS  Google Scholar 

  76. Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003; 39(16):2318-2327.

    Article  PubMed  CAS  Google Scholar 

  77. Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19:2596-2606.

    PubMed  CAS  Google Scholar 

  78. Eiermann W, Paepke S, Appfelstaedt J, LlombartCussac A, Eremin J, Vinholes J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001; 12(11):1527-1532.

    Article  PubMed  CAS  Google Scholar 

  79. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005; 23(22):5108-5116.

    Article  PubMed  CAS  Google Scholar 

  80. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365(9453):60-62.

    PubMed  CAS  Google Scholar 

  81. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353(26):2747-2757.

    PubMed  Google Scholar 

  82. Vergote I, Robertson JFR, Kleeberg U, Burton G, Osborne CK, Mauriac L. Postmenopausal women who progress on fulvestrant ( Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Research and Treatment 2003; 79(2):207-211.

    Article  PubMed  CAS  Google Scholar 

  83. Cheung KL, Owers R, Robertson JFR. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre. Endocrine-Related Cancer 2006; 13(1):251-255.

    Article  PubMed  CAS  Google Scholar 

  84. Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AMH. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Research 2005; 65(12):5439-5444.

    Article  PubMed  CAS  Google Scholar 

  85. Lønning PE. Adjuvant treatment of early breast cancer. Clinics of North America 2006;In press.

    Google Scholar 

  86. Sawka CA, Pritchard KI, Shelley W, DeBoer G, Paterson AHG, Meakin JW, et al. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada clinical trials group (NCIC CTG) trial MA.1. Breast Cancer Res Treat 1997; 44(3):211-215.

    Article  PubMed  CAS  Google Scholar 

  87. Crump M, Sawka CA, DeBoer G, Buchanan RB, Ingle JN, Forbes J, et al. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 1997; 44(3):201-210.

    Article  PubMed  CAS  Google Scholar 

  88. Klijn JGM, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 2001; 19(2):343-353.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Oncology, Department of Medicine, Haukeland University Hospital, N-5021, Bergen, Norway

    Jürgen Geisler

  2. Section of Oncology, Department of Medicine, Haukeland University Hospital, N-5021, Bergen, Norway

    Per Eystein Lønning

Authors
  1. Jürgen Geisler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Per Eystein Lønning
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgery, Cardiff University School of Medicine, Heath Park, CF14 4XN, Cardiff, UK

    Robert E. Mansel MS, FRCS, CBE

  2. Michell Cancer Institute, University of South Alabama, 307 N. University Blvd., 2015, 36688, AL, USA

    Oystein Fodstad PhD

  3. Metastasis and Angiogenesis Research Group, Cardiff University School of Medicine, CF14 4XN, Heath Park, Cardiff, UK

    Wen G. Jiang MB, BCh, MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer

About this chapter

Cite this chapter

Geisler, J., Lønning, P.E. (2007). Hormonal therapies of metastatic breast cancer: the past and the present. In: Mansel, R.E., Fodstad, O., Jiang, W.G. (eds) Metastasis of Breast Cancer. Cancer Metastasis – Biology and Treatment, vol 11. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-5867-7_21

Download citation

Publish with us

Policies and ethics

Search

Navigation